Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease
ABSTRACT Background We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double‐blind manner in Parkinson's disease patients with motor complications in Japan. Methods A total of...
Gespeichert in:
| Veröffentlicht in: | Movement disorders 2013-07, Vol.28 (8), p.1138-1141 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1141 |
|---|---|
| container_issue | 8 |
| container_start_page | 1138 |
| container_title | Movement disorders |
| container_volume | 28 |
| creator | Mizuno, Yoshikuni Kondo, Tomoyoshi |
| description | ABSTRACT
Background
We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double‐blind manner in Parkinson's disease patients with motor complications in Japan.
Methods
A total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.
Results
The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, P = .003) and istradefylline 40 mg/day (−0.96 hours, P = .003) groups compared with the placebo group (−0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).
Conclusions
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment. © 2013 Movement Disorder Society |
| doi_str_mv | 10.1002/mds.25418 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3842830</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3042253591</sourcerecordid><originalsourceid>FETCH-LOGICAL-i3888-e2b889302baf44dc72b2201161e4339d7ba7bd5b3cec45da21aed08e0648acfb3</originalsourceid><addsrcrecordid>eNpVUctOGzEUtVArSIFFf6Cy1AWrAT9n7mwqRdDQVuEhAWKH5RnfgGHiCfakbf6-htCoXVi2dB4-OoeQj5wdcsbE0dylQ6EVhy0y4lryAoSu3pERA9CF5KB3yIeUHhnjXPNym-wIqUCWohqRu7HD0CcfkI7FmEZscTH0kdow2Ps--DTQfKJ1OFt13Qstolu2mKizvlvRi8mEDn6O1Ad6aeOTD6kPBxn1CW3CPfJ-ZruE-2_3LrmZfL0-_lZML06_H4-nhZcAUKBoAGrJRGNnSrm2Eo0QOW3JUUlZu6qxVeN0I1tslXZWcIuOAbJSgW1njdwlX9a-i2UzR9diyJk7s4h-buPK9Nab_5HgH8x9_9NIUAIkywaf3wxi_7zENJjHfhlDzmy44rViClSdWZ_-_Wbj_7fPTDhaE375DlcbnDPzMpTJQ5nXoczZydXrIyuKtSLXjL83ilylKStZaXN7fmp-nF1dTq-hNkr-AfQrliM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1419404849</pqid></control><display><type>article</type><title>Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Mizuno, Yoshikuni ; Kondo, Tomoyoshi</creator><creatorcontrib>Mizuno, Yoshikuni ; Kondo, Tomoyoshi ; Japanese Istradefylline Study Group</creatorcontrib><description>ABSTRACT
Background
We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double‐blind manner in Parkinson's disease patients with motor complications in Japan.
Methods
A total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.
Results
The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, P = .003) and istradefylline 40 mg/day (−0.96 hours, P = .003) groups compared with the placebo group (−0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).
Conclusions
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment. © 2013 Movement Disorder Society</description><identifier>ISSN: 0885-3185</identifier><identifier>EISSN: 1531-8257</identifier><identifier>DOI: 10.1002/mds.25418</identifier><identifier>PMID: 23483627</identifier><identifier>CODEN: MOVDEA</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Adenosine A2 Receptor Antagonists - therapeutic use ; Aged ; Brief Reports ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Humans ; istradefylline ; Japan ; levodopa ; Male ; Middle Aged ; motor complications ; Movement disorders ; Parkinson Disease - drug therapy ; Parkinson's disease ; Purines - therapeutic use ; Retrospective Studies ; Treatment Outcome ; wearing-off</subject><ispartof>Movement disorders, 2013-07, Vol.28 (8), p.1138-1141</ispartof><rights>Copyright © 2013 Movement Disorder Society</rights><rights>Copyright © 2013 Movement Disorder Society.</rights><rights>Copyright © 2013 Movement Disorder Society 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fmds.25418$$EPDF$$P50$$Gwiley$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fmds.25418$$EHTML$$P50$$Gwiley$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23483627$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mizuno, Yoshikuni</creatorcontrib><creatorcontrib>Kondo, Tomoyoshi</creatorcontrib><creatorcontrib>Japanese Istradefylline Study Group</creatorcontrib><title>Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease</title><title>Movement disorders</title><addtitle>Mov Disord</addtitle><description>ABSTRACT
Background
We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double‐blind manner in Parkinson's disease patients with motor complications in Japan.
Methods
A total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.
Results
The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, P = .003) and istradefylline 40 mg/day (−0.96 hours, P = .003) groups compared with the placebo group (−0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).
Conclusions
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment. © 2013 Movement Disorder Society</description><subject>Adenosine A2 Receptor Antagonists - therapeutic use</subject><subject>Aged</subject><subject>Brief Reports</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>istradefylline</subject><subject>Japan</subject><subject>levodopa</subject><subject>Male</subject><subject>Middle Aged</subject><subject>motor complications</subject><subject>Movement disorders</subject><subject>Parkinson Disease - drug therapy</subject><subject>Parkinson's disease</subject><subject>Purines - therapeutic use</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>wearing-off</subject><issn>0885-3185</issn><issn>1531-8257</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNpVUctOGzEUtVArSIFFf6Cy1AWrAT9n7mwqRdDQVuEhAWKH5RnfgGHiCfakbf6-htCoXVi2dB4-OoeQj5wdcsbE0dylQ6EVhy0y4lryAoSu3pERA9CF5KB3yIeUHhnjXPNym-wIqUCWohqRu7HD0CcfkI7FmEZscTH0kdow2Ps--DTQfKJ1OFt13Qstolu2mKizvlvRi8mEDn6O1Ad6aeOTD6kPBxn1CW3CPfJ-ZruE-2_3LrmZfL0-_lZML06_H4-nhZcAUKBoAGrJRGNnSrm2Eo0QOW3JUUlZu6qxVeN0I1tslXZWcIuOAbJSgW1njdwlX9a-i2UzR9diyJk7s4h-buPK9Nab_5HgH8x9_9NIUAIkywaf3wxi_7zENJjHfhlDzmy44rViClSdWZ_-_Wbj_7fPTDhaE375DlcbnDPzMpTJQ5nXoczZydXrIyuKtSLXjL83ilylKStZaXN7fmp-nF1dTq-hNkr-AfQrliM</recordid><startdate>201307</startdate><enddate>201307</enddate><creator>Mizuno, Yoshikuni</creator><creator>Kondo, Tomoyoshi</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>RC3</scope><scope>5PM</scope></search><sort><creationdate>201307</creationdate><title>Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease</title><author>Mizuno, Yoshikuni ; Kondo, Tomoyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-i3888-e2b889302baf44dc72b2201161e4339d7ba7bd5b3cec45da21aed08e0648acfb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenosine A2 Receptor Antagonists - therapeutic use</topic><topic>Aged</topic><topic>Brief Reports</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>istradefylline</topic><topic>Japan</topic><topic>levodopa</topic><topic>Male</topic><topic>Middle Aged</topic><topic>motor complications</topic><topic>Movement disorders</topic><topic>Parkinson Disease - drug therapy</topic><topic>Parkinson's disease</topic><topic>Purines - therapeutic use</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>wearing-off</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mizuno, Yoshikuni</creatorcontrib><creatorcontrib>Kondo, Tomoyoshi</creatorcontrib><creatorcontrib>Japanese Istradefylline Study Group</creatorcontrib><collection>Istex</collection><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Movement disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mizuno, Yoshikuni</au><au>Kondo, Tomoyoshi</au><aucorp>Japanese Istradefylline Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease</atitle><jtitle>Movement disorders</jtitle><addtitle>Mov Disord</addtitle><date>2013-07</date><risdate>2013</risdate><volume>28</volume><issue>8</issue><spage>1138</spage><epage>1141</epage><pages>1138-1141</pages><issn>0885-3185</issn><eissn>1531-8257</eissn><coden>MOVDEA</coden><abstract>ABSTRACT
Background
We evaluated the efficacy and safety of istradefylline, a selective adenosine A2A receptor antagonist administered as adjunctive treatment to levodopa for 12 weeks in a double‐blind manner in Parkinson's disease patients with motor complications in Japan.
Methods
A total of 373 subjects were randomized to receive placebo (n = 126), istradefylline 20 mg/day (n = 123), or istradefylline 40 mg/day (n = 124). The primary efficacy variable was the change in daily OFF time. Other secondary variables were also evaluated.
Results
The change in daily OFF time was significantly reduced in the istradefylline 20 mg/day (−0.99 hours, P = .003) and istradefylline 40 mg/day (−0.96 hours, P = .003) groups compared with the placebo group (−0.23 hours). The most common adverse event was dyskinesia (placebo, 4.0%; istradefylline 20 mg/day, 13.0%; istradefylline 40 mg/day, 12.1%).
Conclusions
Istradefylline reduced daily OFF time and was well tolerated in Japanese PD patients with motor complications on levodopa treatment. © 2013 Movement Disorder Society</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>23483627</pmid><doi>10.1002/mds.25418</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-3185 |
| ispartof | Movement disorders, 2013-07, Vol.28 (8), p.1138-1141 |
| issn | 0885-3185 1531-8257 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3842830 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adenosine A2 Receptor Antagonists - therapeutic use Aged Brief Reports Dose-Response Relationship, Drug Double-Blind Method Female Humans istradefylline Japan levodopa Male Middle Aged motor complications Movement disorders Parkinson Disease - drug therapy Parkinson's disease Purines - therapeutic use Retrospective Studies Treatment Outcome wearing-off |
| title | Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T20%3A30%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Adenosine%20A2A%20receptor%20antagonist%20istradefylline%20reduces%20daily%20OFF%20time%20in%20Parkinson's%20disease&rft.jtitle=Movement%20disorders&rft.au=Mizuno,%20Yoshikuni&rft.aucorp=Japanese%20Istradefylline%20Study%20Group&rft.date=2013-07&rft.volume=28&rft.issue=8&rft.spage=1138&rft.epage=1141&rft.pages=1138-1141&rft.issn=0885-3185&rft.eissn=1531-8257&rft.coden=MOVDEA&rft_id=info:doi/10.1002/mds.25418&rft_dat=%3Cproquest_pubme%3E3042253591%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1419404849&rft_id=info:pmid/23483627&rfr_iscdi=true |